NuProbe, Evive among bolus of venture rounds for Chinese biotechs

Chinese genomics and molecular diagnostics company NuProbe Global raised $50 million in a series B round led by AstraZeneca-CICC Fund, CR-CP Life Science Fund and Panlin Capital. New investors Haoreng Capital, Deguan Asset, Pappas Capital and existing investors Biotrack Capital, Sequoia Capital, Yonghua Capital, Topband also participated in the round. Led by Chai Yingshuang, the company raised $42 million in its series A round last year.

Ten months after its establishment in Suzhou BioBay, Doma Pharmaceutical Technology (Suzhou) Co. Ltd. raised RMB950 million ($143 million) in a series A round to support its life sciences incubator. Investors included parent company Beijing Biocytogen Co. Ltd., China Life Private Equity Investment, PICC Capital Equity Investment, UBS SDIC Fund Management, Suzhou Industrial Park, China Taiping Insurance Group and CMB International. ...